• Mantle cell lymphoma: BTK inhibitors have the highest commercial potential

  The mantle cell lymphoma (MCL) landscape is diverse, containing nine drugs that are aimed at...
  Read More...

• The biggest ever pharmaceutical lawsuits

  Fraudulent and illegal conduct by pharmaceutical companies poses a great risk to public health and...
  Read More...

• Top five most expensive drugs in the US

  Despite criticism on high pricing, pharmaceutical companies continue to maintain the high prices of orphan...
  Read More...

• Pharma Technology Focus: the deep dive for new drugs

  In this issue: exploring the potential of the underwater biome in drug development, nationalised drug...
  Read More...

• Lonafarnib, a hope for progeria treatment

  Lonafarnib has emerged as a potential treatment for progeria and progeroid laminopathies, an ultra-rare condition...
  Read More...

• The longest running clinical trials

  Five of the ten longest running clinical trials are being conducted on drugs targeted at...
  Read More...

• Pharma Technology Focus: digitising the API supply chain

  In this issue: a look back at Scott Gottlieb’s time as FDA commissioner, connecting drugmakers...
  Read More...

• The top selling prescription drugs by revenue

  Humira tops the list despite growing biosimilar competition, while Opdivo and Keytruda, the new-age checkpoint...
  Read More...

• Will Evofem’s non-hormonal contraceptive Amphora become a game-changer?

  Although non-hormonal contraceptive options are greatly sought-after by women of reproductive age, Amphora may only...
  Read More...

• Pharma Technology Focus: is a memory loss drug on the horizon?

  In this issue: the buzz around esketamine, treatments to target memory loss, cannabis in the...
  Read More...